Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety

Author(s): Mingxia Wang, Guanqi Wang, Haiyan Ma, Baoen Shan*

Journal Name: Current Cancer Drug Targets

Volume 19 , Issue 1 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Introduction: Crizotinib was approved to treat anaplastic lymphoma kinase (ALK)- positive non-small cell lung cancer (NSCLC) by the Food and Drug Administration in 2011.We conducted a systematic review of clinical trials and retrospective studies to compare the efficacy and safety of crizotinib with chemotherapy.

Methods: We searched electronic databases from inception to Dec. 2016. Clinical trials and retrospective studies regarding crizotinib and crizotinib versus chemotherapy in treatment of NSCLC were eligible. The primary outcomes were the objective response rate (ORR) and disease control rate (DCR).

Results: Nine studies (five clinical trials and four retrospective studies) including 729 patients met the inclusion criteria. Crizotinib treatment revealed 1-year OS of 77.1% and PFS of 9.17 months. And crizotinib had a better performance than chemotherapy in ORR (OR: 4.97, 95%CI: 3.16 to 7.83, P<0.00001, I2=35%). DCR revealed superiority with crizotinib than chemotherapy (OR: 3.42, 95% CI: 2.33 to 5.01, P<0.00001, I2=0%). PR (partial response) were significant superior to that of chemotherapy through direct systematic review. No statistically significant difference in CR (complete response) was found between crizotinib-treated group and chemotherapy-treated group. Regarding SD (stable disease), chemotherapy-treated group had a better performance than crizotinib-treated group. Common adverse events associated with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, nausea, and hematologic toxicity.

Conclusion: This systematic review revealed improved objective response rate and increased disease control rate in crizotinib group comparing with chemotherapy group. Crizotinib treatment would be a favorable treatment option for patients with ALK-positive NSCLC. ALK inhibitors may have future potential applications in other cancers driven by ALK or c-MET gene mutations.

Keywords: Systematic review, Crizotinib, chemotherapy, Anaplastic lymphoma kinase (ALK), Non-small cell lung cancer (NSCLC).

Shaw, A.T.; Engelman, J.A. ALK in lung cancer: past, present, and future. J. Clin. Oncol., 2013, 44, 1-7.
Steuer, C.E.; Ramalingam, S.S. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging tre-atment options. J. Cancer, 2014, 120(16), 2392-2402.
Zou, H.Y.; Li, Q.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.J.; Kung, P.P.; Nambu, M.D. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res., 2007, 67(9), 4408-4417.
Bergethon, K.; Shaw, A.T.; Ou, S.H.I.; Katayama, R.; Lovly, C.M.; McDonald, N.T.; Massion, P.P.; Siwak-Tapp, C.; Gonzalez, A.; Fang, R.; Mark, E.J. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol., 2012, 30(8), 863-870.
Christensen, J.G.; Zou, H.Y.; Arango, M.E.; Li, Q.; Lee, J.H.; McDonnell, S.R.; Yamazaki, S.; Alton, G.R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther., 2007, 6(12), 3314-3322.
Solomon, B.; Wilner, K.D.; Shaw, A.T. Current status of targeted therapy for anaplastic lymphoma kinase–rearranged non–small cell lung cancer. Clin. Pharmacol. Ther., 2014, 95(1), 15-23.
Pfizer Inc. EU Xalkori (crizotinib) summary of product characteristics. 2014.
Reck, M.; Popat, S.; Reinmuth, N.; De Ruysscher, D.; Kerr, K.M.; Peters, S. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol 2014. 25(suppl_3), iii27-iii39.
Ettinger, D.S.; Akerley, W.; Borghaei, H.; Chang, A.C.; Cheney, R.T.; Chirieac, L.R.; D’Amico, T.A.; Demmy, T.L.; Ganti, A.K.; Govindan, R.; Grannis, F.W., Jr; Horn, L.; Jahan, T.M.; Jahanzeb, M.; Kessinger, A.; Komaki, R.; Kong, F.M.; Kris, M.G.; Krug, L.M.; Lennes, I.T.; Loo, B.W., Jr; Martins, R.; O’Malley, J.; Osarogiagbon, R.U.; Otterson, G.A.; Patel, J.D.; Pinder-Schenck, M.C.; Pisters, K.M.; Reckamp, K.; Riely, G.J.; Rohren, E.; Swanson, S.J.; Wood, D.E.; Yang, S.C.; Hughes, M.; Gregory, K.M. NCCN (National Comprehensive Cancer Network). Non-small cell lung cancer. J. Natl. Compr. Canc. Netw., 2012, 10, 1236-1271.
Fukuoka, M.; Wu, Y.L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.S.; Sriuranpong, V.; Chao, T.Y.; Nakagawa, K.; Chu, D.T.; Saijo, N.; Duffield, E.L. Biomarker analyses and final overall survival results from a phase III,randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-celllung cancer in Asia (IPASS). J. Clin. Oncol., 2011, 29(21), 2866-2874.
American Cancer Society. Cancer Facts & Figures, 2013.
Shaw, A.T.; Yeap, B.Y.; Solomon, B.J.; Riely, G.J.; Gainor, J.; Engelman, J.A.; Shapiro, G.I.; Costa, D.B.; Ou, S.H.I.; Butaney, M.; Salgia, R. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol., 2011, 12(11), 1004-1012.
Shaw, A.T.; Kim, D.W.; Nakagawa, K.; Seto, T.; Crinó, L.; Ahn, M.J.; De Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F.; Wu, Y.L. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med., 2013, 368(25), 2385-2394.
Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.I.; Dezube, B.J.; Jänne, P.A.; Costa, D.B.; Varella-Garcia, M. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med., 2010, 363(18), 1693-1703.
Camidge, D.R.; Bang, Y.J.; Kwak, E.L.; Iafrate, A.J.; Varella-Garcia, M.; Fox, S.B.; Riely, G.J.; Solomon, B.; Ou, S.H.I.; Kim, D.W.; Salgia, R. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol., 2012, 13(10), 1011-1019.
Brosnan, E.M.; Weickhardt, A.J.; Lu, X.; Maxon, D.A.; Barón, A.E.; Chonchol, M.; Camidge, D.R. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer, 2013, 120(5), 664-674.
Berge, E.M.; Lu, X.; Maxson, D.; Barón, A.E.; Gadgeel, S.M.; Solomon, B.J.; Doebele, R.C.; Varella-Garcia, M.; Camidge, D.R. Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non–small-cell lung cancer. Clin. Lung Cancer, 2013, 14(6), 636-643.
Solomon, B.J.; Mok, T.; Kim, D.W.; Wu, Y.L.; Nakagawa, K.; Mekhail, T.; Felip, E.; Cappuzzo, F.; Paolini, J.; Usari, T.; Iyer, S. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med., 2014, 371, 2167-2177.
Cui, S.; Zhao, Y.; Dong, L.; Gu, A.; Xiong, L.; Qian, J.; Zhang, W.; Niu, Y.; Pan, F.; Jiang, L. Is there a progression- free survival benefit of first- line crizotinib versus standard chemotherapy and second- line crizotinib in ALK- positive advanced lung adenocarcinoma? A retrospective study of Chinese patients. Cancer Med., 2016, 5(6), 1013-1021.
Zhang, Q.; Qin, N.; Wang, J.; Lv, J.; Yang, X.; Li, X.; Nong, J.; Zhang, H.; Zhang, X.; Wu, Y.; Zhang, S. Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma. Thorac. Cancer, 2016, 7, 3-8.
Ou, S.H.I.; Tong, W.P.; Azada, M.; Siwak‐Tapp, C.; Dy, J.; Stiber, J.A. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer, 2013, 119, 1969-1975.
Mellor, H.R.; Bell, A.R.; Valentin, J.P.; Roberts, R.R. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci., 2011, 120, 14-32.
Ou, S.H.; Jänne, P.A.; Bartlett, C.H.; Tang, Y.; Kim, D.W.; Otterson, G.A.; Crinò, L.; Selaru, P.; Cohen, D.P.; Clark, J.W.; Riely, G.J. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann. Oncol., 2014, 25, 415-422.
Costa, D.B.; Shaw, A.T.; Ou, S.H.I.; Solomon, B.J.; Riely, G.J.; Ahn, M.J.; Zhou, C.; Shreeve, S.M.; Selaru, P.; Polli, A.; Schnell, P. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J. Clin. Oncol., 2015, 33(17), 1881-1888.
Solomon, B.J.; Cappuzzo, F.; Felip, E.; Blackhall, F.H.; Costa, D.B.; Kim, D.W.; Nakagawa, K.; Wu, Y.L.; Mekhail, T.; Paolini, J.; Tursi, J. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J. Clin. Oncol., 2016, 34(24), 2858-2865.
Gainor, J.F.; Tan, D.S.; De Pas, T.; Solomon, B.; Ahmad, A.; Lazzari, C.; De Marinis, F.; Spitaleri, G.; Schultz, K.; Friboulet, L.; Yeap, B.Y. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin. Cancer Res., 2015, 21(12), 2745-2752.
Dagogo-Jack, I.; Shaw, A.T. Crizotinib resistance: implications for therapeutic strategies. Ann. Oncol., 2016(Suppl. 3), iii42-iii50.
O’Bryant, C.L.; Wenger, S.D.; Kim, M.; Thompson, L.A. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann. Pharmacother., 2013, 47(2), 189-197.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 13 December, 2018
Page: [41 - 49]
Pages: 9
DOI: 10.2174/1568009617666170623115846
Price: $65

Article Metrics

PDF: 71